Outcome Assessment in Case of Severe COVID-19 Patients Treated with Remdesivir

Abstract

Background: A sudden outbreak of a novel coronavirus disease (covid-19) pandemic has thrown challenges in searching out a truly effective drug or vaccine to minimize the heavy toll of mortality and morbidity worldwide. But still, now humanity is lagging in finding such an agent that can be labelled as absolutely efficacious. Methods: We conducted a prospective observational cohorttrial of injectable Remdesivir in the case of hospitalized patients presenting with features of respiratory tract infection and diagnosed as COVID-19 pneumonia by RT-PCR for COVID-19 test and categorized as severe COVID-19 cases as pernational guidelines criteria. Patients were treated with injectable Remdesivir (200mg on day 1, followed by 100 mg daily for up to 05 additional days) along with other standard treatment protocols. The primary outcome of the study was the time to recovery, defined by improvement in clinical and laboratory parameters whether discharge from the hospital or not (hospitalization for infection-control purposes only).